Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies

Br J Haematol. 2021 Dec;195(5):706-709. doi: 10.1111/bjh.17836. Epub 2021 Sep 21.

Thomas A Fox^{1

2}, Amy A Kirkwood³, Louise Enfield², Maeve O'Reilly², Suzanne Arulogun², Shirley D'Sa², Jenny O'Nions², Janki Kavi⁴, Evan Vitsaras⁵, William Townsend², Siobhan O Burns^{1

4}, Satyen H Gohil², Kate Cwynarski², Kirsty J Thomson², Mahdad Noursadeghi^{6

7}, Robert S Heyderman^{6

7}, Tommy Rampling⁷, Kirit M Ardeshna², Laura E McCoy^{1

6}, Emma C Morris^{1

2}

¹ UCL Institute of Immunity and Transplantation, University College London, London, UK.
² Department of Clinical Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
³ CR UK and UCL Cancer Trials Centre, UCL Cancer Institute, UCL, London, UK.
⁴ Immunology, Royal Free London Hospitals NHS Foundation Trust, London, UK.
⁵ Health Services Laboratories, London, UK.
⁶ Research Department of Infection, University College London, London, UK.
⁷ Department of Infectious Disease, University College London Hospitals NHS Foundation Trust, London, UK.

No abstract available

Keywords: B-cell malignancy; CAR-T; COVID-19; vaccination.

Publication types